The stock of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) last traded at $4.09, down -1.45% from the previous session.
FDMT stock price is now 16.35% away from the 50-day moving average and -35.67% away from the 200-day moving average. The market capitalization of the company currently stands at $189.47M.
With the price target reduced from $40 to $15, BMO Capital Markets Downgraded its rating from Outperform to Market Perform for 4D Molecular Therapeutics Inc (NASDAQ: FDMT). On November 21, 2024, Morgan Stanley recently initiated its ‘Underweight’ rating on the stock quoting a target price of $8, while ‘Cantor Fitzgerald’ rates the stock as ‘Neutral’
In other news, Bizily Scott, Chief Legal Officer sold 500 shares of the company’s stock on Sep 16 ’24. The stock was sold for $8,165 at an average price of $16.33. Upon completion of the transaction, the Chief Legal Officer now directly owns 6,781 shares in the company, valued at $27734.29. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 19 ’24, Chief Legal Officer Bizily Scott sold 500 shares of the business’s stock. A total of $7,500 was realized by selling the stock at an average price of $15.00. This leaves the insider owning 6,781 shares of the company worth $27734.29. A total of 10.31% of the company’s stock is owned by insiders.
During the past 12 months, 4D Molecular Therapeutics Inc has had a low of $2.23 and a high of $28.93. As of last week, the company has a debt-to-equity ratio of 0.05, a current ratio of 12.36, and a quick ratio of 12.36.
The net profit margin was -767126.09% and return on equity was -32.97% for FDMT. The company reported revenue of $14000.0 for the quarter, compared to $28000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -50.0 percent.
